诺华：降胆固醇药物乐可为 （英克司兰钠注射液）在中国新增获批单药治疗适应症

Core Viewpoint - Novartis announced the approval of its innovative cholesterol-lowering drug, Inclisiran (injectable), by the National Medical Products Administration of China, which will be used as an adjunct to diet for adults with primary hypercholesterolemia (non-familial) or mixed dyslipidemia to lower low-density lipoprotein cholesterol (LDL-C) [1] Group 1 - Inclisiran has received approval to expand its indications beyond previous approvals for use with statins or in combination with statins and other lipid-lowering therapies, thereby covering more patients with dyslipidemia [1] - As a targeted PCSK9 small interfering RNA cholesterol-lowering drug, Inclisiran's biannual dosing regimen is expected to enhance treatment adherence and improve long-term LDL-C target achievement rates, aiding in the long-term management of lipid levels [1]